Navigation Links
Laparoscopic Surgeons Develop Fluorescent Light Technique to Improve Pancreatic Cancer Detection
Date:10/24/2011

SAN FRANCISCO, Oct. 24, 2011 /PRNewswire-USNewswire/ -- More than 80 percent of people with pancreatic cancer are diagnosed after the cancer has metastasized, and by then the prognosis for long-term survival is dismal.  However, surgeons and scientists at the University of California-San Diego (UCSD) are developing a laparoscopic technique that uses fluorescent light to improve pancreatic cancer staging and treatment.  Their findings were presented today at the 2011 Clinical Congress of the American College of Surgeons.

The UCSD researchers compared a standard xenon laparoscope with a laparoscope using a light emitting diode (LED) source.  Surgeons took two antibodies that are commonly expressed by pancreatic cancer and tagged them with a fluorescent marker, thus, making the cancerous tumors "light up" in colors of bright green or red, reported study leaders, Michael Bouvet, MD, FACS, and Robert M. Hoffman, Ph.D., both UCSD professors of surgery.

The surgeons and scientists then administered fluorescent antibodies into six-week old female mice.  The researchers were able to see primary and metastatic tumors more vividly with the LED light, at a sensitivity rate of 96 percent, than with traditional laparoscopy, which had a sensitivity rate of 40 percent.  Moreover, fluorescent laparoscopy rendered fewer false positives than traditional laparoscopy, and the researchers were able to clearly see the surrounding anatomy in the abdominal cavity of the mice.  Fluorescent laparoscopy was also sensitive enough to illuminate metastatic lesions smaller than one millimeter, which are not visible with a standard laparoscope.

"Laparoscopy is used for staging in patients with cancer, often before we make a big incision," said Dr. Bouvet.  "Now, we've made it even better with the LED light source.  We modified it so you can see both the normal background of the anatomy plus the fluorescent tumor signal at the same time.  We were able to perform LED fluorescence laparoscopy in mice with small, three millimeter laparoscopes."

The fluorescent marker did not show evidence of toxicity or side effects in the mice.  The combination of LED light and fluorescent markers for malignant tumors could potentially sharpen how surgeons detect and treat pancreatic cancer in human patients.  If patients have received the fluorescent antibodies prior to an operation, the surgeon can insert the LED laparoscope through a small incision and determine if the cancer has metastasized to other areas of the abdomen.  "If it has spread, then we can biopsy those areas and better determine if the best initial treatment should be chemotherapy and save the patient the large incision," Dr. Bouvet said.  "If there's no or limited metastases, then we can more completely remove the primary and metastatic tumors because we can see the edges better.  We're hoping for a lower rate of local recurrence."

Once the cancerous tumors are illuminated, Dr. Bouvet explains, the surgeons are able to more precisely remove the tumor and any surrounding malignant tissue without injuring the aorta and other nearby blood vessels.  Furthermore, another potential application for this technique could involve medically treating pancreatic cancer: "You could tag a specific drug or isotope to target tumor cells.  Since the fluorescent antibodies bind specifically to cancer cells, you could deliver certain payloads of drugs that would kill the cancer cells more effectively," Dr. Bouvet said.

The technique could also be applied to staging and treating colon cancer, which often is expressed through the same antibodies as pancreatic cancer and treated with the same laparoscopic technology.  Within the next four years, Dr. Bouvet plans to work with OncoFluor, Inc., a biotech company that develops fluorescent compounds for malignant tumors, on securing FDA approval for clinical trials of the fluorescent antibodies in humans.

Other members of the research team included Cristina Angela Metildi Raimo, MD; Sharmeela Kaushal, Ph.D.; Chanae Hardamon, BSc, Hop Tran Cao, MD; Cynthia S. Snyder, MD; George A. Luiken, MD; and Mark A. Talamini, MD, FACS, all from the University of California-San Diego, San Diego, CA;  OncoFluor, Inc., San Diego, CA; and AntiCancer, Inc., San Diego, CA.

NOTE: The UCSD research team worked with AntiCancer, Inc. on the mouse model and with laparoscope technicians at Stryker Corporation.  The research is funded by a five-year grant to UCSD and AntiCancer, Inc. from the National Cancer Institute.


'/>"/>
SOURCE American College of Surgeons
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Surgeons Find That Laparoscopic Banding Procedure Helps Overweight Adolescents Lose Weight and Improve Health
2. Internationally Renowned Bariatric and Laparoscopic Surgeons To Meet in San Diego
3. CareFusion Signs Exclusive Partnership Agreement With Minimally Invasive Devices to Distribute FloShield Laparoscopic Technology
4. PolyTouch Medical Ltd. Receives FDA Clearance to Commercialize PatchAssist(TM) - an Innovative Surgical Instrument Intended to Facilitate the Delivery of Soft Tissue Prosthetics During the Laparoscopic Repair of Soft Tissue Defects
5. Steerable Technologix LLC Announces Release of SurgiSteer Laparoscopic Instruments
6. Simbionix and USF Receive Grant to Support Development of Laparoscopic Hysterectomy Simulation
7. Solos Endoscopy, Inc. Strengthens Current Line of Laparoscopic Instruments
8. Dr. Andreas Kuthe Performs First Laparoscopic Procedures Using Cardicas Microcutter XPRESS™ 30 Surgical Cutting and Stapling Device
9. New Micro Laparoscopic Instruments for the Bariatric Surgery Allow for Less Scarring and Pain than Ever Before Possible
10. Ethicon Endo-Surgery Introduces First Powered Endocutter with Enhanced System-Wide Compression and Stability, Allowing Surgeons Greater Control in Laparoscopic Surgery
11. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... One of Australia,s successful biotechnology scientists, Dr ... biotechnology company, Noxopharm Limited [ABN 50 608 966 123] ("Noxopharm"). Noxopharm ... on the ASX. Noxopharm is a clinic-ready company with ... 1 clinical study later this year. ... problems facing cancer patients - the ability of cancers to become ...
(Date:6/26/2016)... DUBLIN , June 27, 2016 Jazz ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... proposed acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... 11:59 p.m. (Eastern Daylight Time). As previously ... entered into a definitive merger agreement under which Jazz ...
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
(Date:6/24/2016)... TX (PRWEB) , ... June 24, 2016 , ... People ... part in Genome magazine’s Code Talker Award, an essay contest in which patients and ... an award to be presented at the 2016 National Society of Genetic Counselors (NSGC) ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... actively feeding the Frederick area economy by obtaining investment capital for emerging technology ... past 2½ years that have already resulted in more than a million dollars ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th ... Woodmont Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised ... have been wounded in battle and their families. Venture Construction Group is a 2016 ...
Breaking Medicine News(10 mins):